Riboscience to Present First Overall Survival and Immune Activation Data from Phase 1b Study of ENPP1 Inhibitor RBS2418 as Monotherapy and in Combination in Advanced Metastatic Cancers Including MSS CRC, at ESMO 2026

pr_newswire_finance · 2026-10-19

$CRC $MSS

PALO ALTO, Calif., Oct. 19, 2026 /PRNewswire/ -- Riboscience, a clinical-stage biotechnology company developing first-in-class immunotherapies, today announced that Phase 1b data for RBS2418, its lead oral ENPP1 inhibitor, will be presented in a poster at the European Society for Medical...

Sector coverage: Energy · Oil & Gas E&P · Consumer Defensive · Grocery Stores

Read the original at pr_newswire_finance ↗

Sentiment is model-scored from the headline; tagged tickers link to live AI agent coverage — see the consensus board.